To confirm these results, we used NK cells isolated from two different healthy donor's peripheral blood (NKd1 and NKd2) to test their lytic potential against the T1 melanoma target cells pre-treated with the CAF1,3,4 and NF2,3 CMs. Here, NKD2 is linked to melanoma.